Chairperson of the board
INVESTOR RELATIONS
The Code of Business Conduct and Ethics was last amended effective March 31, 2022. The areas addressed by the changes include: (i) general language & considerations to guide application of the Code, (ii) broader goal-oriented language in regards to R&D and Regulatory compliance, (iii) conflicts of interest, (iv) maintenance of corporate books, records, documents and accounts, financial integrity, public reporting, (v) gifts and entertainment, (vi) dealings with government officials, (vii) compliance with the Foreign Corrupt Practices Act, (viii) prohibition against discrimination/equal opportunity employment, (ix) health and safety guidelines, (x) protection and proper use of company assets, (xi) waivers, and (xii) compliance standards and procedures. This summary is qualified in its entirety by reference to the full text of the Code of Business Conduct and Ethics.
Name | Audit Committee | Compensation Committee | Nominating and Corporate Governance Committee |
---|---|---|---|
Harold E. “Barry” Selick, Ph.D. | |||
Bryan Giraudo | |||
Sarah O’Dowd | |||
Dinesh V. Patel, Ph.D. | |||
William D. Waddill | |||
Lewis T. “Rusty” Williams, M.D., Ph.D. |
Chairperson of the board
Financial Expert
Committee Chair
Committee Member
Privacy Policy | Terms of Use | © 2024 Protagonist Therapeutics Inc. All Rights Reserved.
Spotlight, Arturo Molina, MD, Chief Medical Officer
At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.
Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.
We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.
Spotlight: Carena Spivey, Head of HR
We view our diverse and welcoming corporate culture as being critical to our long-term success – It’s essential to the way we innovate. And we regularly track and report our progress, because we believe that what doesn’t get measured doesn’t get done.
Today:
- 65% of employees are members of underrepresented ethnic communities
- 51% are women
- nearly 50% of our Board identifies as a member of an underserved community or as female
We create the conditions for our employees to thrive, facilitating their learning and growth through a richly supportive workplace setting.
Part of that is creating a speak-up culture; we have cultivated an environment where every voice is heard, and we encourage the expression of different points of view in decision-making processes. At every turn, we encourage deep listening, thoughtful consideration, and open-mindedness that allows for decisions to be changed or refined in step with new data. By embracing our team members’ differences, we create wins for our organization and for patients.